Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Melatonin added to bupropion or varenicline for nicotine withdrawal symptoms
IRCT20261008071350N1Phase 3Recruiting
- Sponsor
- Shiraz University of Medical Sciences
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of melatonin, bupropion and varenicline in nicotine dependence (4 arms), sponsored by Shiraz University of Medical Sciences. Primary endpoints: Anxiety, Depression and 3 more. Started Oct 2026; status: recruiting.
02
Drugs
melatoninbupropionvarenicline
03
Conditions
nicotine dependence
Beyond the preview
Go deeper on IRCT20261008071350N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20261008071350N1.